Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 9 Years.
Phase of Trial: Phase III
Latest Information Update: 09 May 2017
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 09 Feb 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2009-015960-32).
- 01 Nov 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 04 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.